FibroGen第二季度每股收益$（1.88）击败$（2.25）估计，销售额135万美元低于263万美元估计

FibroGen (NASDAQ: FGEN) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(2.25) by 16.44 percent. This is a 53 percent increase over losses of $(4.00) per share from the same period last year. The company reported quarterly sales of $1.35 million which missed the analyst consensus estimate of $2.63 million by 48.75 percent. This is a 97.34 percent decrease over sales of $50.64 million the same period last year.